
## Dorte Linnemann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7985401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related <scp><i>RAS</i></scp> and <scp><i>BRAF</i></scp> mutation status. International Journal of Cancer, 2021, 148, 2542-2556.	2.3	4
2	Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. Apmis, 2020, 128, 3-9.	0.9	3
3	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 5027.	1.8	7
4	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clinical Cancer Research, 2020, 26, 5655-5667.	3.2	21
5	Three years of colorectal cancer screening in Denmark. Cancer Epidemiology, 2018, 57, 39-44.	0.8	57
6	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer, 2017, 17, 48.	1.1	17
7	Validity of data in the Danish Colorectal Cancer Screening Database. Clinical Epidemiology, 2017, Volume 9, 105-111.	1.5	46
8	Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. Scientific Reports, 2016, 6, 26997.	1.6	6
9	Seeding after ultrasound-guided percutaneous biopsy of liver metastases in patients with colorectal or breast cancer. Acta Oncológica, 2016, 55, 638-643.	0.8	16
10	The prognostic value of polycomb group protein Bâ€cellâ€specific moloney murine leukemia virus insertion site 1 in stage <scp>II</scp> colon cancer patients. Apmis, 2016, 124, 541-546.	0.9	4
11	SOX9 expression predicts relapse of stage II colon cancer patients. Human Pathology, 2016, 52, 38-46.	1.1	24
12	Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. British Journal of Cancer, 2016, 114, 134-137.	2.9	73
13	Outcome of cetuximab plus irinotecan in relation to <i>RAS</i> and <i>BRAF</i> mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan Journal of Clinical Oncology, 2016, 34, e15115-e15115.	0.8	0
14	MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. BMC Cancer, 2015, 15, 1024.	1.1	27
15	Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. American Journal of Physiology - Renal Physiology, 2015, 308, G92-G99.	1.6	18
16	Topoisomeraseâ€1 and â€2A gene copy numbers are elevated in mismatch repairâ€proficient colorectal cancers. Molecular Oncology, 2015, 9, 1207-1217.	2.1	23
17	Clinical Implications of Intestinal Stem Cell Markers in Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 63-71.	1.0	34
18	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. PLoS ONE, 2014, 9, e109430.	1.1	39

#	Article	IF	CITATIONS
19	Seeding after biopsy of liver metastases in patients with primary colorectal and breast cancer Journal of Clinical Oncology, 2014, 32, e14545-e14545.	0.8	0
20	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer Journal of Clinical Oncology, 2013, 31, 3572-3572.	0.8	2